LifeMD (LFMD)
(Real Time Quote from BATS)
$10.30 USD
+0.12 (1.18%)
Updated Mar 28, 2024 03:54 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Income Statements
Fiscal Year end for LifeMD, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 153 | 119 | 93 | 37 | 12 |
Cost Of Goods | 19 | 19 | 18 | 9 | 3 |
Gross Profit | 134 | 100 | 75 | 28 | 9 |
Selling & Adminstrative & Depr. & Amort Expenses | 148 | 144 | 129 | 86 | 12 |
Income After Depreciation & Amortization | -14 | -43 | -54 | -58 | -3 |
Non-Operating Income | 0 | 0 | -4 | -1 | 0 |
Interest Expense | 3 | 1 | 3 | 2 | 1 |
Pretax Income | -17 | -45 | -61 | -60 | -4 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 3 | 1 | 0 | -2 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -18 | -45 | -61 | -61 | -4 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -21 | -46 | -61 | -59 | -3 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -8 | -31 | -51 | -57 | -2 |
Depreciation & Amortization (Cash Flow) | 7 | 13 | 3 | 1 | 1 |
Income After Depreciation & Amortization | -14 | -43 | -54 | -58 | -3 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 33.91 | 30.98 | 27.01 | 14.28 | 9.90 |
Diluted EPS Before Non-Recurring Items | -0.70 | -1.57 | -1.48 | -4.44 | -0.35 |
Diluted Net EPS (GAAP) | -0.70 | -1.57 | -2.29 | -4.44 | -0.35 |
Fiscal Year end for LifeMD, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 | |
---|---|---|---|---|---|
Sales | 44.86 | 38.61 | 35.95 | 33.13 | 28.12 |
Cost Of Goods | 5.36 | 4.78 | 4.55 | 4.21 | 4.07 |
Gross Profit | 39.50 | 33.83 | 31.40 | 28.91 | 24.05 |
SG&A, R&D, and Dept/Amort Expenses | 41.68 | 38.40 | 36.29 | 31.76 | 31.94 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.18 | -4.57 | -4.89 | -2.85 | -7.89 |
Non-Operating Income | 0.00 | 0.00 | 0.00 | -0.33 | -2.49 |
Interest Expense | 0.62 | 0.71 | 1.00 | 0.26 | 0.84 |
Pretax Income | -2.79 | -5.28 | -5.89 | -3.44 | -11.21 |
Income Taxes | 0.43 | 0.00 | 0.00 | 0.00 | 0.36 |
Minority Interest | 0.51 | 0.84 | 0.84 | 0.57 | 0.36 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -3.22 | -5.28 | -5.89 | -3.44 | -11.58 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -3.73 | -6.12 | -6.73 | -4.01 | -11.94 |
Earnings Per Share Data | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 |
---|---|---|---|---|---|
Average Shares | 36.71 | 34.47 | 32.56 | 31.68 | 31.41 |
Diluted EPS Before Non-Recurring Items | -0.12 | -0.20 | -0.23 | -0.15 | -0.40 |
Diluted Net EPS (GAAP) | -0.12 | -0.20 | -0.23 | -0.15 | -0.40 |